Reported 1 day ago
Argus has initiated coverage of DexCom, Inc. (NASDAQ:DXCM) with a Buy rating and a price target of $100. The firm expects DexCom to maintain strong growth above the industry average, increase profitability through cost leverage, and expand its customer base in the continuous glucose monitoring market for diabetes management. DexCom's robust free cash flow enables significant R&D investments for product innovation. The current share price is seen as an attractive entry point for investors.
Source: YAHOO